title: [The role of surgical therapy for esophageal microcytoma. Experience of there clinical cases and results analysis].
abstract: Small cell carcinoma of the esophagus is a rare tumor. It was described for the first time in 1952 by McKeown and 200 cases have been reported till now. Because of its similarity with small cell carcinoma of the lung, the treatment of this tumor is controversial. In our Institute we treated three patients with small cell carcinoma of the esophagus. All subjects underwent subtotal esophagectomy with esophagogastroanastomosis through laparotomic and thoracotomic approach. Histologically, the tumor was classified as pure SCEC in one patient and mixed SCEC in the other two. The stage I and II patients received operation as single treatment. The two patients are alive and disease free 219 and 193 months after surgery. The third patient, classified at stage III, underwent postoperative chemotherapy but local and distant recurrence was observed 11 months after surgical resection. He was submitted to a second choice chemotherapy, but he died 24 months after the operation. The long-term survival observed in our two patients treated by surgery is the longest described in literature. Our experience seems to demonstrate that an early diagnosis and oncological radical resection, may be helpful in the long-term prognosis even in presence of a very aggressive neoplasm.
authors: Divisione di Chirurgia Toracica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy. ppbm@virgilio.it
authors: P P
authors: PP
authors: Brega-Massone
authors: B
authors: B
authors: Conti
authors: C
authors: C
authors: Lequaglie
authors: F
authors: F
authors: Ferro
authors: I
authors: I
authors: Cataldo
mesh_terms: D000368:Aged; D000714:Anastomosis, Surgical / Q000379:methods; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016629:Esophagectomy / Q000379:methods; D004944:Esophagoplasty / Q000379:methods*; D004945:Esophagoscopy / Q000379:methods; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007813:Laparotomy / Q000379:methods; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012074:Remission Induction; D013270:Stomach / Q000601:surgery; D013908:Thoracotomy / Q000379:methods; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D016685:Mitomycin; D014747:Vinblastine; D005047:Etoposide; D016190:Carboplatin; D000077235:Vinorelbine